ARTICLE | Preclinical News
Anti-GD2 CAR T could treat midline gliomas
April 16, 2018 9:54 PM UTC
A study published in Nature Medicine suggests that CAR T cells targeting ganglioside GD2 could help treat diffuse midline gliomas with mutated histone H3 K27M.
GD2 has been identified as a target to treat cancers such as neuroblastoma. However, treatment options are limited for diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas with the H3 K27M mutation -- aggressive and fatal pediatric brain cancers...
BCIQ Target Profiles